Rakovina Therapeutics Inc.
RKV.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.58% | 100.05% | 334.64% | 334.64% | 358.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.84% | 72.35% | 269.63% | 269.63% | 187.30% |
| Operating Income | 27.84% | -72.35% | -269.63% | -269.63% | -187.30% |
| Income Before Tax | 20.68% | -74.48% | -251.50% | -251.50% | -172.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.68% | -74.48% | -251.50% | -251.50% | -172.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.68% | -74.48% | -251.50% | -251.50% | -172.16% |
| EBIT | 27.84% | -72.35% | -269.63% | -269.63% | -187.30% |
| EBITDA | 30.03% | -84.62% | -327.79% | -327.79% | -233.97% |
| EPS Basic | 49.58% | 26.00% | -56.25% | -56.25% | -35.55% |
| Normalized Basic EPS | 52.52% | 26.11% | -56.23% | -56.23% | -35.34% |
| EPS Diluted | 46.71% | 26.00% | -51.08% | -51.08% | -35.55% |
| Normalized Diluted EPS | 52.52% | 26.11% | -56.23% | -56.23% | -35.34% |
| Average Basic Shares Outstanding | 57.19% | 135.85% | 125.00% | 125.00% | 100.86% |
| Average Diluted Shares Outstanding | 57.19% | 135.85% | 125.00% | 125.00% | 100.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |